EXPERIMENTAL CHEMOTHERAPY WITH 5-ARYLPYRIMIDINE ANTIFOLATES - PRELIMINARY STUDIES OF TOXICITY AND RESPONSIVENESS OF SARCOMA 180 TO DDMP (NSC-19494) AND DDMP WITH CITROVORUM FACTOR (NSC-3590)
- 1 January 1976
- journal article
- research article
- Vol. 60 (5) , 547-553
Abstract
The 5-arylpyrimidine antifolate DDMP [2,4-diamino-5-(3,4-dichlorophenyl)-6-methylpyrimidine] showed appreciable therapeutic activity against an ascitic form of sarcoma 180 in BD2F1 mice. Antitumor effects were schedule and dose dependent at a limited number of doses within the range of 8-40 mg/kg. The best results (increased lifespan = 112%) were obtained with 2 doses of DDMP at 40 mg/kg given 4 days apart. The incorporation of citrovorum factor rescue in dose schedules with DDMP appeared to improve the therapeutic index. In multiple dose schedules with citrovorum factor allowing an average of 8 doses of DDMP at a maximum level of 16 mg/kg, increases in median lifespan were > 158% with a number of long-term survivors.This publication has 4 references indexed in Scilit:
- Uptake as a Determinant of Methotrexate Response in Mouse LeukemiasScience, 1965
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ACTION AND EFFECTS OF FOLIC ACID ANTAGONISTS1963
- EFFECT OF DELAYED ADMINISTRATION OF CITROVORUM FACTOR ON THE ANTILEUKEMIC EFFECTIVENESS OF AMINOPTERIN IN MICE1954
- STUDIES OF THE ACTION OF 4‐AMINOPTEROYLGLUTAMIC ACID AND ITS CONCERNS IN MAMMALSAnnals of the New York Academy of Sciences, 1950